The Scintilla team is comprised of experienced leaders in pharmaceutical product development, commercialization and business development.
Chief Executive Officer, Scintilla Pharmaceuticals, Inc.
Jaisim Shah currently serves as the Chief Executive Officer and board member of Scintilla Pharmaceuticals and is a board member of Sorrento Therapeutics, Inc. He was CEO, Co-founder and President of Semnur Pharmaceuticals, Inc. from 2013 until 2016. Prior to Semnur, Jaisim was a consultant to several businesses, including his current role as board member… read more »
Dmitri Lissin, M.D.
Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs
Dmitri Lissin currently serves as Chief Medical Officer of Scintilla Pharmaceuticals. He was Senior Vice President, Clinical Development and Medical Affairs of Semnur Pharmaceuticals from 2015 to 2016. Prior to Semnur, from 2011-2015, Dmitri was Vice President of Clinical Development at Xenoport, responsible for conduct of multiple clinical research programs in neurology and dermatology. From… read more »
Glen Sato, J.D.
Legal/ Interim Chief Financial Officer
Glen Sato currently is a partner at Cooley LLP and is supporting Scintilla Pharmaceuticals as Interim Chief Financial Officer and Legal support. Glen is responsible for the finance, operations and legal activities of Scintilla Pharmaceuticals and has extensive experience in public offerings, financing and collaborative transactions as well as operational experience in both research and… read more »
Suketu D. Desai, Ph.D.
Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls
Suketu D. Desai, Ph.D., currently serves as Chief Technical Officer of Scintilla Pharmaceuticals. He was Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls (CMC) at Semnur Pharmaceuticals, Inc. in 2016. Prior to Semnur, during 2014-2015, Suketu was Vice President of Biologics Development and Manufacturing responsible for biologics drug substance and drug product,… read more »
Bryan Jones, Ph.D.
Vice President, Operations
Bryan Jones is Vice President of Operations of Scintilla Pharmaceuticals. He was Vice President, Operations of Sorrento Therapeutics from 2013 to 2016 and President/CSO of its subsidiary, ARK Animal Health, from 2014 to 2016. He has led development of resiniferatoxin for treatment of pain associated with inflammation. He has written an ANDA in canines for… read more »